THANK YOU FOR SUBSCRIBING
EXUMA Biotech Corp. plans to use the funds to advance its new logic gated CAR-T therapies for solid tumor malignancies and for further improvement and partnering of its rapid point-of-care (or "rPOC"), same-day CAR-T platform technology
FREMONT, CA: EXUMA Biotech Corp., a clinical-stage biotechnology corporation discovering and developing Chimeric Antigen Receptor (CAR)-T cell products for solid tumors, announced the closure of $19M Series B round of financing. MSD Partners and F1 BioVentures joined the round of financing as new investors, besides other individuals.
EXUMA Biotech Corp. plans to use the funds to advance its new logic gated CAR-T therapies for solid tumor malignancies and for further improvement and partnering of its rapid point-of-care (or "rPOC"), same-day CAR-T platform technology.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
To better reflect its business model, EXUMA has aligned management with its global subsidiaries under one cohesive organization. "We are now moving forward together as one company. The timing was right for us to create a unified global platform to leverage our synergistic capabilities, which we believe will ultimately allow us to produce and deliver CAR-T products even more efficiently for the millions of people worldwide in need of cutting-edge treatments in their fight against cancer," said Gregory Frost, Ph.D., Chairman, and CEO of EXUMA Biotech Corp.
Scott Segal and Frank McCormick joined the existing directors David Ramsay, and Gregory Frost, post the investment. "We are pleased to welcome these new Directors to the EXUMA board; their collective experience will be invaluable as we advance through several key inflection points in 2020," said Dr. Frost. "This will be a tremendous year for the company as we continue the development of these exciting new platforms, especially rPOC, which can help make cellular therapies more readily accessible to patients around the world."
[vendor_logo_first]Scott Segal, the Managing Director at MSD Partners, invests across a range of sectors, in both structured equity and debt. Prior to that, he was in Boston Consulting Group, providing consulting services to Fortune 500 executives. Whereas Frank McCormick, Ph.D., F.R.S., D.Sc is a Professor at the UCSF Helen Diller Family Comprehensive Cancer Center.
See Also: Top Biotech Solution Companies
More in News